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ABSTRACT 
 
Rationale: The diabetes drug metformin is under investigation in cardiovascular disease but the 
molecular mechanisms underlying possible benefits are poorly understood.  
 
Objective: Here we have studied anti-inflammatory effects of the drug and their relationship to anti-
hyperglycaemic properties. 
 
Methods and Results: In primary hepatocytes from healthy animals, metformin and the IKKinhibitor 
BI605906 both inhibited TNF-dependent IB degradation and expression of pro-inflammatory 
mediators IL-6, IL-1 and CXCL1/2. Metformin suppressed IKK activation, an effect which could 
be separated from some metabolic actions, in that BI605906 did not mimic effects of metformin on 
lipogenic gene expression, glucose production and AMPK activation. Equally AMPK was not required 
either for mitochondrial suppression of IB degradation. Consistent with discrete anti-inflammatory 
actions, in macrophages metformin specifically blunted secretion of pro-inflammatory cytokines, 
without inhibiting M1/M2 differentiation or activation. In a large treatment naïve diabetes population 
cohort, we observed differences in the systemic inflammation marker, Neutrophil to Lymphocyte Ratio 
(NLR), following incident treatment with either metformin or sulfonylurea monotherapy. Compared to 
sulfonylurea exposure, metformin reduced the mean log-transformed NLR after 8-16 months by 0.09 
units (95% CI=0.02-0.17, p=0.013), and increased the likelihood that NLR would be lower than baseline 
after 8-16 months (OR 1.83, 95% CI=1.22-2.75, p=0.00364). Following up these findings in a double 
blind placebo controlled trial in nondiabetic heart failure (trial registration: NCT00473876), metformin 
suppressed plasma cytokines including the ageing-associated cytokine CCL11.  
 
Conclusion: We conclude that anti-inflammatory properties of metformin are exerted irrespective of 
diabetes status. This may accelerate investigation of drug utility in non-diabetic cardiovascular disease 
groups. 
 
Name of the trial registry: Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction 
(TAYSIDE Trial)  
Registry's URL: https://clinicaltrials.gov/show/NCT00473876  
Trial registration number: NCT00473876 
 
Keywords:  
Metformin, NF-B, inflammation, heart failure, cardiovascular disease, metabolism, diabetes mellitus, 
pharmacology. 
 
Nonstandard Abbreviations and Acronyms: 
 
18S  18S ribosomal RNA 
ACC  acetyl-CoA carboxylase 
ACE  angiotensin-converting enzyme 
AICAR  5-aminoimidazole-4-carboxamide riboside 
AMPK   adenosine monophosphate-activated protein kinase 
ANOVA analysis of variance 
BMDM  bone marrow derived macrophages 
BMI   Body Mass Index 
CCL11   C-C motif chemokine ligand 11 
CCL22  C-C motif chemokine ligand 22 
cDNA   complementary deoxyribonucleic acid 
CHF   congestive heart failure 
CVD   Cardiovascular Disease 
CXCL1   chemokine (C-X-C motif) ligand 1 
CXCL2  chemokine (C-X-C motif) ligand 2 
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DM   Diabetes Mellitus 
EDTA   ethylenediaminetetraacetic acid 
EGTA   ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
FASN   fatty acid synthase 
FBS   fetal bovine serum 
FIRI   Fasting Insulin Resistance Index 
GoDARTs  Genetics of Diabetes Audit and Research in Tayside Scotland 
HRP   horseradish peroxidase 
hsCRP   high sensitivity C-reactive protein 
IFN  interferon gamma 
IKK   inhibitor of kappa B kinase 
IL-1   interleukin-1 
IL-10   interleukin-10 
IL-12p40  interleukin-12p40 
IL-1β   interleukin-1β 
IL-2   interleukin-2 
IL-6   interleukin-6 
IR   Insulin Resistant 
KO   knock-out 
LPS   lipopolysaccharide 
M-CSF  macrophage colony-stimulating factor 
mTOR   mammalian target of rapamycin 
NFB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR   Neutrophil to Lymphocyte Ratio  
NSAIDs  nonsteroidal anti-inflammatory drug 
OR   Odds Ratio  
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PDI p  ropanediimidamide 
PMSF   phenylmethylsulfonyl fluoride 
PPAR   peroxisome proliferator-activated receptor gamma 
RNA   ribonucleic acid 
SDF1αβ  stromal cell-derived factor 1 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM   Standard Error of Mean 
SREBP-1c  sterol regulatory element-binding protein 1 
T2D   Type 2 Diabetes 
TAK1   transforming growth factor beta-activated kinase 1 
TBP   TATA-binding protein 
TLR   toll-like receptor 
TNFα    tumour necrosis factor alpha 
VE/VCO2  minute ventilation/carbon dioxide production 
VO2   oxygen consumption 
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INTRODUCTION 
 
Metformin is the first line drug in type 2 diabetes (T2D) because compared with other T2D 
treatments, in both clinical trials and in observational studies metformin monotherapy is associated with 
fewer adverse cardiovascular events (1; 2), and in some studies, a reduced risk of cancer (3). The reasons 
for this relative benefit are unclear and metformin’s molecular action is a vigorous area of current 
research (4-7). Metformin’s chemical properties include a strongly hydrophilic character, metal-binding 
properties and a pKa within the physiological pH range (6-8). The key clinical hallmark of metformin’s 
anti-hyperglycaemic action is suppression of hepatocyte gluconeogenesis (4; 5; 9). The most likely 
cellular effect underlying this response is inhibition of mitochondrial enzymes, including complex I in 
the electron transport chain (10; 11). More recently mitochondrial glycerophosphate dehydrogenase 
(mGPD) has been suggested as an alternative target (12). Mitochondrial inhibition activates AMPK 
(13) and recent work suggests that duodenal AMPK contributes towards effects of the drug on hepatic 
glucose production (14). Other studies indicate that metformin suppresses glucose production by 
AMPK-independent mechanisms (12; 15; 16) but more broadly, AMPK may still contribute to 
metformin-dependent regulation of other aspects of metabolic control, such as lipogenic gene 
expression (4).  
 
The mechanism(s) underlying metformin’s advantage in incidence of cardiovascular disease 
are unlikely to depend on effects of the drug on hyperglycaemia, which is controlled equally well by 
metformin and insulin secretagogues (2). In addition, in animals, metformin suppresses infarct size and 
adverse remodelling in diabetic and non-diabetic rodents (17-21) and retards heart failure progression 
in non-diabetic dogs (22). A better understanding of such glucose-independent properties might foster 
a more rational, less empirical exploitation of metformin in nondiabetic cardiovascular disease. 
Inflammation, including NF-B signaling, is increasingly recognised as a significant contributing factor 
to diabetes and cardiovascular disease (23; 24) and several previous studies have found that metformin 
inhibits NF-B signaling, including in vascular tissue (25) and recently in hepatocytes (26). In the 
current study, we have utilised multiple approaches including human studies, to define anti-
inflammatory actions of metformin that may be separated from its anti-hyperglycaemic action.  
 
METHODS 
 
Animal and cell studies.  
Metformin and rapamycin came from Calbiochem, AICAR and A769662 (Tocris), TNF(e-
bioscience), recombinant CINC1/CXCL1, CCL-11, IL-2, IL-4, SDF and CCL22 (R&D systems), 
mouse IL-6 (Sigma) and recombinant mouse IL-1β (Life Technologies). The phospho-acetyl-CoA 
carboxylase (ACC) Ser79 antibody was a generous gift from the DSTT (University of Dundee). The 
total ACC (Cat. number 3662), total AMPK(2603), phospho-AMPK Thr172 (2535), total S6 (2217), 
phospho-S6 Ser240/244 (2215), total p70 S6 kinase (2708), phospho-p70 S6 kinase Thr389 (9205), 
phospho-Raptor Ser 792 (2083), phospho IKK Ser176/177 (2078), IKK Ser176/180 (2697), total 
IB, pNF-B, total IKK and total IKK (NF-B sampler kit 9936) antibodies were from CST. Anti-
sheep HRP (31480) and anti-rabbit HRP (31460) both came from Thermo and anti-mouse HRP was 
from Calbiochem (JA1200). BI605906 was generously gifted by Prof Sir Philip Cohen (Dundee). 
 
Animal care.  
C57BL/6 female mice (Charles River, 8-41 weeks) were maintained under a 12 hours:12 hours 
light:dark cycle (holding room lights on at 06:00; off at 18:00) at 22±1◦C and 50% humidity. Mice had 
ad libitum access to standard chow diet (7.5% fat, 75% carbohydrate and 17.5% protein by energy 
(RM1 diet; Special Diet Services) and water. All animal care protocols and procedures were performed 
in accordance with current regulations.  
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Cell culture and lysis for immunoblotting. 
All cells were grown in an incubator at 37ºC and 5% CO2. Primary mouse hepatocytes were extracted 
and maintained essentially as described previously (6; 15). 
 
BMDMs were grown from mouse bone marrow in RPMI 1640 medium supplemented with 10% FBS 
(foetal bovine serum; Life Technologies) and 10ng/ml M-CSF (R&D systems). Cells were given fresh 
medium and growth factor on day 3 of culture. On day 6, BMDM cultures were supplemented with 
100ng/ml IFNγ (for M1 differentiation; R&D systems), 20ng/ml IL-4 (for M2 differentiation; R&D 
systems), or 100ng/ml LPS (for activation; premium grade from Sigma, expected to activate TLR2 and 
TLR4) in the presence or absence of drug treatments for the final 24h. 
 
Prior to SDS-PAGE, cells were lysed by scraping into buffer A: (50mM Tris acetate pH7.5, 1% (w/v) 
Triton X100, 1mM EDTA, 1mM EGTA, 0.27M sucrose, 50mM NaF, 1mM sodium orthovanadate, 
10mM -glycerophosphate, 5mM sodium pyrophosphate, 1mM benzamidine, 0.2mM 
phenylmethylsulfonyl fluoride (PMSF) and 0.1% (v/v) -mercaptoethanol) then prepared for SDS-
PAGE as described in previous work (6). Immunoblot densitometry for each antibody was performed 
with Image Studio Lite version 5.2 (LI-COR). Each blot is representative of experiments carried out at 
least three times. 
 
Glucose assay. 
Treatment of cells for hepatocyte glucose production was performed essentially as described previously, 
using primary mouse hepatocytes plated in 12-well plates (1.25 x 105 cells/well) (6; 15; 27). Glucose 
production was determined after a 12 hour incubation period in glucose-free DMEM (11966; Life 
Technologies) supplemented with 1% pen/strep, lactate (Sigma)/pyruvate (Life Technologies) (10:1 
mM) and 100nM dexamethasone (dex; Merck) with or without drugs/cytokines under investigation. At 
the end of the incubation period of 12 hours, 500µl of medium was collected and glucose concentration 
determined by GAGO assay (Sigma) by a modified protocol scaled down to a 96-well plate format. 
Each column consists of data from at least 12 wells of cells, six each from two mice. 
 
RT-PCR. 
Total RNA from primary mouse hepatocytes was extracted using QIAshredder (Qiagen) and Rneasy 
MINI KIT (Qiagen). cDNA was synthesized using RQ1 Rnase-Free Dnase kit (Promega) and ImProm-
II Reverse Transcription System (Promega). Nucleospin RNA II Total RNA isolation kit (Macherey-
Nagel) was used to isolate RNA from macrophages. cDNA was synthesized using High Capacity cDNA 
Reverse Transcription Kit (4368814, Thermo Fisher Scientific). Real-time PCR was carried out using 
the 7900HT Fast Real-Time PCR System (Applied Biosystems) using TaqMan 2x Universal PCR 
Master Mix (Applied Biosystems) and primer/probes mixes as stated (Applied Biosystems). Primer sets 
used were: IL-6 Mm00446190_ml; CXCL1 Mm04207460_m1; 18S Hs03003631_g1; IL-1β 
Mm00434228_m1; CXCL2 Mm00436450_m1; PPARγ Mm01184322_m1; FASN 
Mm00662319_m1; CCL22 Mm00436439_ml; CXCL12 Mm00445553_ml; TBP Mm01277042_m1 
and SREBP-1c Mm00550338_m1. Cycling conditions were: 50°C for 2 min, 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 s and 60°C for 1 min. Expression is expressed relative to 18s mRNA for 
hepatocytes and TBP for macrophages (Applied Biosystems) using the 2-ΔΔCt method. Each column is 
composed of data from at least three separate experiments. 
 
BMDM analysis. 
BMDMs were harvested from culture plates using 4mM EDTA in PBS for 10min at 37°C. Cells were 
washed in flow cytometry buffer (PBS with 2% FBS and 1mM EDTA) and stained using the following 
antibodies (all BD Bioscience unless stated): F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 
(C068C2; Biolegend), CD69 (H1.2F3) and CD40 (3/23). Fc block (4.4G2) was included in all stains. 
Data were acquired on a LSR II flow cytometer (Becton Dickinson) and analysed using FlowJo software 
(TreeStar). BMDM culture supernatants were collected after 24 hours treatment with the differentiation 
or activation conditions. Levels of cytokines were quantified by standard sandwich ELISA using paired 
antibody kits (e-bioscience). 
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Validation in clinical patients. 
We validated the animal study findings in clinical patients utilizing 2 approaches: A retrospective 
population cohort study and a randomized placebo controlled study of metformin. All patients provided 
written informed consent to participate in these clinical studies that were approved the local ethics 
committee. 
 
Population cohort study: Diabetes patient Metformin exposure and Neutrophil-to-Lymphocyte Ratio 
(NLR). 
In the population cohort study, we investigated whether or not the anti-inflammatory signature of 
metformin could be detected in humans with diabetes, using the GoDARTS (Genetics of Diabetes Audit 
and Research in Tayside Scotland) diabetes register (28). We compared the effect of metformin and 
sulfonylureas on the Neutrophil to Lymphocyte Ratio (NLR), a marker of inflammation derived from 
a combination of haematological components of the systemic inflammatory response (29; 30) that has 
recently been found to be a predictor of all-cause mortality and cardiac events (31). We analysed data 
from T2D patients recruited in Tayside, Scotland, UK, between 1 October 1997 and 1 March 2010. Of 
the 9,205 subjects with diabetes within the GoDARTS study, we chose 3,575 treatment naïve patients 
who were either incident metformin users or incident sulfonylurea users (but not both), and non-insulin 
users. Incident use meant at least 6 months prior to first observed metformin/sulfonylurea prescription 
date during which they were observable for drugs. Of these 670 patients (mean (SD) age 65 (11) years, 
54% males) had derived NLR values both at baseline (up to 120 days prior to first 
metformin/sulfonylurea prescription) and follow-up (8-16 months after baseline). NLR was calculated 
as the ratio of the neutrophil to lymphocyte count, both obtained from the same blood sample. 498 
(74%) were treated with metformin and 172 (26%) with sulfonylurea. Multivariate linear and logistic 
regression models were run on the 8-16 month follow-up NLR against the treatment group, controlling 
for covariates including age, sex, and baseline NLR value.  
 
Randomised placebo controlled study: Metformin exposure and cytokine levels in non-diabetic heart 
failure patients. 
The anti-inflammatory effects of metformin were investigated in a randomly selected subset of patients 
who had participated in a double-blind, placebo-controlled study (www.clinicaltrials.gov: 
NCT00473876) that had evaluated the impact of metformin on IR and exercise capacity in non-diabetic 
patients with CHF (35). Every patient had provided written informed consent prior to participation in 
this study, which was approved by the East of Scotland Research Ethics Service. The subset of patients 
selected for this study involved 33 non-diabetic IR CHF patients (mean age, 63 ± 7.0 years; male, 85%; 
New York Heart Association class I/II/III/IV, 04/28/01/0) who were randomized to receive either 4 
months of metformin (n = 20, 2 g/day) or matching placebo (n = 13). IR was defined by a fasting insulin 
resistance index (FIRI) ≥2.7. The effect of metformin on plasma inflammatory cytokines was examined 
by investigating changes from baseline to final visit after 4 months in the study.  
 
Cytokine assay. 
Human plasma was analysed using the Bio-Plex Pro Human Chemokine 40-Plex Panel (171-
AK99MR2, Bio-Rad). The assay was performed following the manufacturer’s instructions using the 
Bio-Plex 200 system (Bio-Rad). Freeze-thaw cycling of samples was avoided to prevent cytokine 
degradation and they were diluted 1:4 (12.5µl of plasma) for the assay. 
 
Statistical analyses. 
Results in bar graphs are expressed as mean ± SEM. Comparisons between groups were made by one-
way ANOVA with Dunnett’s or Tukey post-hoc test using Prism. Differences were considered 
statistically significant if P was less than 0.05. *** denotes p<0.001; ** denotes p<0.01 and * denotes 
p<0.05. For studies on the plasma, statistical analyses of data were performed using SPSS 14.1. 
ANOVA and Pearson correlation coefficients were calculated.  
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RESULTS  
 
Metformin inhibits TNF dependent NF-B inflammatory signaling, comparably with the specific 
IKK inhibitor BI605906. 
 
In primary mouse hepatocytes, the main target of metformin’s anti-hyperglycaemic effects, we 
compared metformin with the specific IKKinhibitor BI605906 (32). Metformin treatment for 3 hours 
suppressed TNF-induced degradation of the NF-B negative regulator IB, whilst modulating AMPK 
and mTOR signaling in a dose-dependent manner (Fig. 1a-c. All densitometry appears in online 
supplementary material). The magnitude of the effect on IB was comparable with BI605906 (Fig. 
1a,d). Unlike metformin, BI605906 did not suppress signaling downstream of mTOR, nor did it activate 
AMPK (Fig. 1e,f). We were unable to detect any effect of rapamycin on NF-B signaling either (Fig. 
1d), suggesting that the effect of metformin on NF-B and mTOR occur independently. Consistent with 
these signaling results, TNF-dependent expression of CINC-1/CXCL1, CXCL2, IL-1and IL-6 was 
strongly inhibited by both metformin and BI605906 (Fig. 1g-j).  
 
AMPK-independent regulation of NFB in primary hepatocytes. 
 
 To determine whether metformin directly regulated kinase activity that may mediate its effects 
on NF-B signaling, a cell-free kinase profiling assay was performed. Metformin did not directly inhibit 
the upstream NF-B regulator IKKand most other kinases exhibited little if any inhibition by 
metformin and none were inhibited >50% (data available on the profiling website http://www.kinase-
screen.mrc.ac.uk/). These results suggest that metformin is unlikely to exert effects on NF-B through 
direct IKKinhibition, or inhibition of other kinases. The lack of effect of metformin on kinase activity 
led us to explore the possibility that IB regulation might occur as a consequence of AMPK activation 
(13) which occurs following mitochondrial inhibition by the drug (10; 11). In side-by-side experiments, 
we treated primary hepatocytes with AICAR (an AMP mimetic) and A769662, a direct AMPK 
activator. Compared with AICAR, which suppressed IB degradation, there was little if any effect of 
A769662 on IB degradation at the doses used (Fig. 2a) but both agents induced phosphorylation of the 
AMPK substrate acetyl CoA carboxylase (ACC, Fig. 2b). To investigate possible reason(s) for this 
difference, we investigated primary liver cells from AMPK catalytic subunit deficient mice (15). In 
these cells, AICAR still suppressed IB degradation (Fig. 2c), suggesting the AICAR effect is AMPK-
independent. Consistent with this, the effect of metformin on IB signaling was similar in both 
genotypes (Fig. 2d). 
 
Dissociation of anti-inflammatory responses from effects of metformin on hepatic glucose production 
and lipogenic gene expression. 
 
 Metformin’s main anti-hyperglycaemic effect is to reduce hepatic glucose production. To 
determine whether metformin-regulated cytokines directly altered glucose production we incubated 
hepatocytes with and without metformin, IL-6, IL-1, CXCL1 and TNF. CXCL1 significantly 
increased glucose production (Fig. 3a). In all groups, metformin reduced glucose production to below 
control levels (basal) in the presence or absence of cytokine. Incubation of hepatocytes with BI605906 
did not mimic the effect of metformin, nor was there any modulation of metformin’s suppression of 
glucose production (Fig. 3b). 
 
 Next we compared the effect of metformin and BI605906 on lipogenesis, which is another 
metabolic response known to be regulated by metformin. Pro-inflammatory cytokines including TNF 
are known to induce lipogenesis (33). This prompted us to study the effects of TNF on lipogenic genes 
SREBP-1c, PPAR and FASN, which are known to be regulated by metformin in hepatocytes (13; 34; 
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35). TNF significantly increased FASN mRNA expression, with a trend towards increased expression 
of SREBP-1c and PPAR (Fig. 3c-e). Metformin reduced mRNA expression of all three genes and 
prevented TNF-induced increases. In contrast to the inflammatory genes, co-incubation of BI605906 
and TNFincreased lipogenic gene expression (Fig. 3c-e). BI605906 alone did not alter SREBP-1c, 
FASN or PPAR, however this compound significantly augmented TNF-induced expression of each 
gene. This may be related to the existence of negative feedback loops in NF-B signaling (32). 
 
Direct anti-inflammatory effect of metformin on macrophage cytokine secretion.  
 
 Our evidence that metformin inhibits inflammatory responses in hepatocytes independently of 
some metabolic actions, prompted us to study inflammatory responses in extrahepatic tissues. 
Macrophages may undergo ‘classical’ pro-inflammatory M1 activation in response to cues including 
LPS and IFN. However, in response to agents including IL-13 and IL-4, they may become M2 cells, 
which are generally thought of as having anti-inflammatory or tissue repair actions (36). We studied 
the effects of metformin and another drug biguanide (BIG, structurally this drug is the same as 
metformin except that it lacks the two methyl groups present in metformin), which we have found 
previously acts similarly to metformin on hepatocytes (6). We investigated three aspects: macrophage 
differentiation, activation and secretion of cytokines. We measured effects on bone marrow derived 
macrophage (BMDM) differentiation into M1 and M2 macrophages, using expression of CD11c as a 
marker of M1 differentiation and CD206 as a measure of M2 differentiation. In addition, we 
investigated macrophage activation in response to LPS, which acts on the toll-like receptor TLR4, 
increasing expression of CD69 and CD40. There was no significant effect of the drugs on expression 
of any of these markers (Fig. 4a,b). As in hepatocytes, metformin suppressed IL-1gene expression in 
macrophages (Online Figure IIIa), but somewhat reminiscent of the effect of BI605906 on lipogenic 
genes, metformin increased expression of the other cytokines we had studied in hepatocytes (Online 
Figure IIIb-d). We did however observe further drug-induced reductions when we measured cytokine 
secretion, to investigate macrophage activity and differentiation more directly. The three cytokines we 
studied were inflammatory cytokines IL-12p40, IL-6 and the anti-inflammatory cytokine IL-10 in these 
TLR-triggered cells. Both drugs reduced IL-12p40 and IL-6 secretion but were without effect on IL-10 
secretion (Fig. 4c-e).  
 
Chronic treatment of hepatocytes with low doses of metformin triggers anti-inflammatory signaling 
responses similar to those resulting from high-dose acute treatment. 
 
 Plasma levels of metformin in the clinical setting are understood to be in the low micromolar 
range (4; 9). Consequently, metformin-treated individuals may have lower intracellular concentrations 
of metformin than in our cell experiments but the duration of exposure will be much longer. 
Discrepancies in effective concentrations of metformin likely occur due to the length of exposure, as 
the drug must accumulate in active mitochondria over several hours (10; 37).  In hepatocytes, long-term 
(24 hours) effects of the drug on NF-B signaling occurred at concentrations close to the physiological 
range and this was unaffected by genotype (Fig. 5a-c).  
 
 To provide more insight into the site of metformin action, we investigated signaling further 
‘upstream’ of IKK(Fig. 5a). We found that TNF-induced phosphorylation of the upstream kinase 
(TAK1) site p176/177 (38) on IKK was suppressed by metformin. In supporting studies, we found 
that PDI, a close structural analogue of metformin that we have found does not inhibit the mitochondria 
(6), does not inhibit IB degradation, nor does it suppress phosphorylation of IKK(Fig. 5a) 
Consistent with the notion that NF-B signaling can respond to mitochondrial inhibition independently 
of AMPK, we found that the complex I inhibitor rotenone prevented TNF-dependent IB degradation 
in both genotypes (Fig. 5d). 
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Anti-inflammatory effects of metformin in a diabetes population cohort. 
 
 Next we compared the effect of metformin and sulfonylureas on the Neutrophil to Lymphocyte 
Ratio (NLR), a marker of inflammation that has recently been found to be a predictor of all-cause 
mortality and cardiac events (31). To test the hypothesis that metformin reduces inflammation using the 
GoDARTS diabetic cohort, we chose individuals prescribed metformin alone (without sulfonylurea or 
insulin) or sulfonylurea alone (without metformin or insulin), and for whom NLR measurements were 
available in the 120 days prior to first metformin/sulfonylurea prescription (the baseline measure), and 
12 months following the first prescription (within a 8-16 months window). There were 498 people in 
metformin group and 172 in sulfonylurea group. Baseline characteristics of the two groups are shown 
in Table 1a. Comparison of the two groups showed a significant effect of metformin exposure compared 
to sulfonylurea, with 12 month log-transformed NLR 0.09 lower in the metformin group, (95% CI 
= (0.02, 0.17), p=0.01), controlling for baseline values. This is equivalent to a 9%, (95% CI = (2%-
15%)) lower geometric mean NLR. In addition, a logistic regression of 12 month NLR being lower than 
the baseline NLR gave an odds ratio of 1.83, (95% CI = (1.22, 2.75), p=0.0034)  for the metformin 
group compared to the sulfonylurea group (Tables 1b,d). BMI both nearest baseline and follow up (4% 
missing) was not a significant variable (p=0.7), so was excluded. Inclusion of baseline HbA1c (19% 
missing) in the models resulted in similar effects. To examine the effect of metformin on high values 
on NLR, the models were rerun including only subjects with baseline NLR above the respective group 
median values (Tables 1 c,e). These showed a stronger metformin effect in the linear model, equivalent 
to a 15% (95% CI 5%-23%) lower geometric mean NLR, and an unchanged metformin effect for the 
logistic model, OR=1.91 (1.02-3.59). These results are summarised in Table 1f. 
 
 To control for the different characteristics of the metformin and sulfonylurea groups, further 
analyses following propensity score matching were performed. Nearest-neighbour one-to-one matching 
on DM duration, BMI, age and ACE exposure at baseline resulted in a reduced matched cohort of 318 
(47% of original). Re-fitting the linear model using this cohort showed a similar effect of metformin 
exposure compared to sulfonylurea, with 12 month log-transformed NLR 0.10 lower in the metformin 
group (95% CI = (0.01, 0.20), p=0.03). The logistic model for 12 month NLR lower than the baseline 
NLR gave an odds ratio of 1.53 for the metformin group compared to the sulfonylurea group, however 
this effect was not statistically significant (95% CI = (0.93, 2.52), p=0.096).  
 
Effect of metformin on inflammation in nondiabetic heart failure. 
 
 Given evidence that the anti-inflammatory effects of metformin may be dissociated from some 
metabolic responses in cells and from glycaemic responses in diabetes, we further investigated the anti-
inflammatory effects of metformin in a placebo controlled clinical trial of metformin in a group of non-
diabetic insulin resistant heart failure patients (39). In this study, compared with placebo, metformin 
significantly improved Fasting Insulin Resistance Index (FIRI) and resulted in a significant reduction 
in weight loss of 1.9 kg and body mass index (BMI). Metformin treatment also reduced the pre-specified 
secondary endpoint of the slope of the ratio of minute ventilation to carbon dioxide production 
(VE/VCO2 slope) (39). We analysed plasma from 33 patients who took part in this study and carried 
out multivariate analysis of variance on all 40 cytokines with treatment (with and without metformin, 
20 allocated to metformin and 13 to placebo) as the main factor and change in BMI as a covariate. This 
covariate analysis identified five cytokines that were significantly suppressed by metformin, after 
controlling for change in BMI (Table 2a). Investigating these cytokines further, we carried out Pearson 
correlations to identify cytokines significantly affected by metformin that correlated with a change in 
BMI. Amongst the five cytokines, correlations were observed for two out of the five cytokines, CCL22 
and CXCL12 (Table 2b). Metformin improved insulin sensitivity as shown by significant reduction in 
FIRI (t = 2.765, df = 30.762) p<0.01 when an independent sample t-test (equal variances not assumed) 
is performed; however, there was no significant correlation between change in FIRI and any change in 
the cytokines in the panel using a Pearson correlation. When a second correction for change in FIRI 
was applied, in addition to change in BMI, four of the five original cytokines remained significantly 
different with treatment (Table 2a).  
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 Most of the cytokines suppressed by metformin in plasma were not measurable in hepatocytes 
or macrophages and for those that could be measured, metformin did not inhibit their expression in 
these cell types (Online Figure IV). Similar to our earlier studies, these cytokines had little if any effect 
on inducing glucose production in hepatocytes and metformin could still suppress this parameter in 
their presence (Fig. 5e). All details of cytokine changes, metabolic, haemodynamic and other 
parameters of these patients are described in Online Tables I and II.  
 
 
 
DISCUSSION 
 
 We have used pharmacological and genetic approaches to isolate anti-inflammatory effects of 
metformin from those on glucose in cells, plasma, patient records and in a placebo controlled study. 
Initiating the study in hepatocytes, we separated signaling effects of metformin on the metabolic 
regulator AMPK from effects on inflammatory signaling. Although the AMPK activator AICAR 
induced similar effects to metformin on IB degradation, AMPK was not required for these effects. In 
long-term treatment, effects of metformin on NF-B signaling occurred at concentrations towards the 
physiological range and in further studies, we found that PDI, a close structural analogue of metformin 
that does not inhibit the mitochondria (6), does not inhibit IB degradation, nor does it increase 
phosphorylation of IKK as is observed with metforminConsistent with the possibility that NF-B 
signaling can respond to mitochondrial inhibition independently of AMPK, we found that metformin 
and rotenone each prevented TNF-dependent IB degradation in an AMPK-independent manner. 
Considering information from these pharmacological and genetic experiments, our data indicates that 
metformin acts upstream of IKKthrough an AMPK-independent mechanism dependent on 
mitochondrial inhibition. This mechanism is fully consistent with our other observations that metformin 
does not directly inhibit IKK in vitro. These studies do not exclude the possibility of AMPK-dependent 
mechanisms contributing to anti-inflammatory actions of metformin in other ways. Effects of 
metformin on anti-inflammatory signaling pathways were separable from other metabolic responses to 
the drug. Inhibition of NF-B signaling had little effect for example on glucose production or lipogenic 
gene expression, two key metabolic actions of metformin. Moreover, addition of cytokines suppressed 
by metformin either in hepatocytes, plasma or macrophages, did not block the effect of the drug on 
glucose production. Taken together, these results define a dual action of metformin, with anti-
inflammatory effects occurring alongside known anti-hyperglycaemic and other metabolic effects. 
These two strands are both likely to be triggered by a mitochondrial target of the drug.  
 
 The evidence that metformin can suppress inflammatory signaling independently of some of its 
metabolic effects led us to investigate non-hepatic anti-inflammatory responses. Previous studies have 
suggested that inflammatory signaling on macrophages influences insulin sensitivity in other tissues. 
Loss of the LPS receptor TLR4 for example confers some protection from insulin resistance following 
a high-fat diet (40). In addition, M2 macrophages dominate in adipose tissue in lean mice, whilst M1 
macrophages accumulate in adipose tissue during obesity, and are thought to contribute to systemic 
insulin resistance (41). At the level of gene expression there were some differences between the effect 
of metformin in hepatocytes and macrophages, although IL-1β was suppressed in both cell types. 
Studying cytokine secretion from macrophages, we found that metformin acted highly selectively to 
reduce pro-inflammatory cytokine secretion from activated macrophages, without affecting anti-
inflammatory cytokine secretion and markers of macrophage differentiation and activation. This 
targeted mechanism may allow selective ablation of the ability of M1 macrophages to induce systemic 
insulin resistance in obesity. Taken together with the results in hepatocytes, this work suggests that 
metformin’s anti-inflammatory actions are likely to be qualitatively different from conventional non-
steroidal anti-inflammatory drugs (NSAIDs).  
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 We wished to establish whether the effects of metformin could be detected in humans and we 
started with a diabetes cohort. Investigating the GoDARTS patient database, we found evidence of 
metformin reducing subclinical inflammation as measured by NLR in patients. It is noteworthy that our 
findings support previous reports that metformin is capable of suppressing markers of inflammation 
such as hsCRP in pre-diabetic individuals (42) and TNF in insulin resistant individuals (43). NLR has 
recently been identified as a predictor of all-cause mortality and cardiovascular events (31) while 
previous studies demonstrated a substantial beneficial effect of metformin therapy on cardiovascular 
outcomes (2; 44; 45). Together, these results suggest that suppression of chronic inflammation by 
metformin might contribute to the difference in outcomes between these two treatment modalities.  
 
 Finally, given the evidence from cells that anti-inflammatory and metabolic effects of the drug 
can be separated, we studied a non-diabetic insulin-resistant heart failure cohort from a randomised 
controlled trial. Our research question was to determine whether or not metformin suppressed plasma 
cytokines. We observed a general trend of metformin treatment lowering cytokine concentrations. 
Correcting for change in BMI, five cytokines were significantly suppressed by metformin but only two 
of these, CCL22 and SDF 1also correlated with change in BMI in follow-up analysis, suggesting 
that in individuals with established CVD, metformin exerts anti-inflammatory effects that are at least 
in part independent of BMI. Four of the five cytokines remained significant after additional correction 
for FIRI and there was no significant correlation between change in FIRI and any of the cytokines in 
the panel using a Pearson correlation, even though metformin did reduce FIRI. Together these data 
strongly suggest that metformin has effects above and beyond the known effects on BMI and insulin 
sensitivity. The identity of these five cytokines signpost ways in which anti-inflammatory effects of 
metformin could exert diabetes-independent therapeutic effects in CVD. One earlier cohort study for 
example found that a Thr/Ala substitution in the CCL11 gene increases risk of myocardial infarction 
independently of BMI and diabetes (46). Blockade of CCL11 can suppress aspects of age-related 
cellular dysfunction (47) and it is possible that observed effects of metformin on mammalian longevity 
(48; 49), where suppression of NF-B is also observed (49), may owe at least in part to suppression of 
this cytokine. The other cytokines SDF 1 IL-2 and IL-4 and CCL22 are each implicated in resolution 
of pancreatic beta cell inflammation (50-53) and SDF 1, IL-2 and IL-4 are additionally upregulated 
in plasma from T2D individuals (54; 55). Further work will be required to determine how the effects 
on macrophages and hepatocytes that we have measured contribute to the changes in plasma cytokines 
observed. Changes in other inflammatory cell types, particularly neutrophils given the change in NLR, 
or in cell-cell interactions, may need to be taken into account. Altogether our results are consistent with 
metformin exerting a potentially cardioprotective anti-inflammatory effect in CVD patients, 
suppressing both age and metabolic inflammatory stress markers, independently of effects on BMI, 
insulin sensitivity and without the onset of frank diabetes.  
 
 We recognize the limitations that are inherent in retrospective, non-randomized, observational 
cohort data. It was impossible to account for all possible confounding influences that may have biased 
the observed differences between the groups considered. For example, the BMI of the two groups is 
different, consistent with historical prescribing patterns (Table 2). We have sought to minimize these 
as far as practicable by three different sensitivity analyses. First, by using a multivariate model adjusting 
for potential confounders; second, by performing a propensity score-matched analysis and thirdly, we 
detected an anti-inflammatory signal in a randomized double blinded placebo-controlled trial, providing 
definitive evidence of anti-inflammatory effects of metformin in this group of patients. The propensity 
score–matched analysis has been shown to eliminate as much as 90% of treatment bias in observational 
studies (56). Due to the small size of the clinical trial, this proof of concept study was designed and 
powered only to investigate the study-specific end point of peak oxygen uptake (VO2) in patients with 
heart failure and not on clinical outcome. However, we have previously shown in a large population-
based cohort study that patients with diabetes and heart failure who were treated with metformin alone 
or in combination with sulfonylureas were at significantly lower risk of all-cause mortality during 1 
year and long-term follow-up than those who were treated with sulfonylurea alone (44). Our findings 
on metformin and inflammation will now similarly need to be confirmed in other patient cohorts. 
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 In summary, cross-species evidence from cells, plasma, patient records and a randomized 
placebo controlled study strongly suggest that anti-inflammatory effects should be investigated further 
as a potentially important aspect of metformin’s clinical pharmacology, that may particularly accelerate 
investigation of their utility in non-diabetic cohorts. There is overwhelming evidence that inflammation 
contributes to the development of cardiovascular disease (24) but counterbalancing this is evidence 
from meta-analysis of randomised control trials that existing NSAIDs tend to exacerbate risk of 
cardiovascular disease (57). If inflammation is to be targeted successfully in cardiovascular disease, 
new treatment paradigms will need to be established. It is likely for example that agents targeting only 
selected aspects of inflammation will need to be identified. Our work identifying discrete anti-
inflammatory effects of metformin on cell signaling and plasma parameters independently of diabetes 
supports ongoing and prospective investigation into repurposing metformin in a broader spectrum of 
patients with cardiovascular disease. 
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FIGURE LEGENDS 
 
Figure 1. Effect of metformin on NF-B signaling and gene expression. 
(a-c) Primary hepatocytes were incubated in serum-free medium overnight and then stimulated for 3h 
with or without 0.5-2mM metformin. For the last 15 min cells were treated with or without 10ng/ml 
TNFCells were lysed and prepared for immunoblotting using antibodies as described in the methods. 
In this figure and elsewhere, each blot is representative of experiments carried out at least three times. 
(d-f) Primary hepatocytes were incubated as in (a-c), prior to stimulation for 3h with or without 2mM 
metformin and TNF. In addition, cells were incubated with/without 10M BI605906 or 100nM 
rapamycin as shown, prior to lysis and immunoblotting as described in the methods. (g-j) Primary 
hepatocytes were treated with or without 10ng/ml TNF2mM metformin or 10M BI605906 for 8h 
followed by cell lysis, RNA extraction and preparation of cDNA for RTPCR using primer sets for 
individual genes shown as described in the methods. 
 
Figure 2. Effect of AICAR and A769662 on NF-B signalling. 
(a-d) Primary wild type hepatocytes (a,b) and those taken from double-knockout (KO) AMPK animals 
or matched controls (WT) (c), were incubated in serum-free medium overnight, prior to stimulation for 
3h with or without doses of A769662 and AICAR as shown. For the last 15 minutes cells were treated 
with or without 10ng/ml TNF(d) Hepatocytes from KO or WT animals treated with and without 
doses of metformin for 3h. For the last 15 minutes cells were treated with 10ng/ml TNF. Cells were 
then lysed and immunoblots prepared as described in the methods and Fig. 1. 
 
Figure 3. Effects of cytokines on glucose production and lipogenic gene expression in primary 
hepatocytes. (a, b) Primary hepatocytes were treated with/without metformin (2mM), IL-6 (5ng/ml), 
IL-1 (10ng/ml), CXCL1 (100ng/ml) and TNF(10ng/ml) for 12h and glucose production was 
measured by GAGO assay as described in the Methods. (c-e) Primary hepatocytes were treated with 
or without 10ng/ml TNF2mM metformin and 10M BI605906 for 8h followed by cell lysis, RNA 
extraction and preparation of cDNA for RTPCR using primer sets for individual genes shown as 
described in the methods. 
 
Figure 4. Effect of metformin and its analogue biguanide on bone marrow-derived macrophages: 
phenotypic markers and cytokine secretion.  
(a) Macrophages were treated with/without metformin (2mM) or biguanide (BIG 2mM) to determine 
the effect on the M1 and M2 phenotypes of macrophages, which was measured by flow cytometry for 
CD11c and CD206 expression. The colours denote the following: Red – undifferentiated; Blue – 
differentiated, untreated; Orange – differentiated, Metformin; Green – differentiated, BIG. (b) 
Macrophages were treated with/without metformin (2mM) or biguanide (BIG, 2mM) to determine the 
effect on activation in response to 100ng/ml LPS, which was measured by studying CD69 and CD40 
expression. Histograms are representative of N=4. The colours denote the following: Red – unactivated; 
Blue – activated, untreated; Orange – activated, Metformin; Green – activated, BIG. (c-e) Macrophages 
were treated with/without metformin (Met) or biguanide (BIG, 2mM) to determine the effect of these 
drugs on IL-6 (c), IL-12p40 (d) and IL-10 (e) production. N=4. 
 
Figure 5. Effect of long-term metformin treatment on NF-B signaling responses in hepatocytes 
(a,b) Primary hepatocytes were treated as in Fig. 1 with metformin or PDI at the doses indicated except 
that the treatment time was 24h. For the last 15 minutes cells were treated with 10ng/ml TNF. In 
addition to antibodies used elsewhere, phosphorylation of IKK was investigated using the 
phosphospecific antibodies indicated. After cell lysis, SDS-PAGE and immunoblotting was carried out 
as in Fig. 1. (c,d) Hepatocytes from wild-type (WT) and AMPK double knockout (KO) livers treated 
as in (a) or with doses of rotenone for 45 min prior to cell lysis, SDS-PAGE and immunoblotting. (e) 
Primary hepatocytes were treated in the presence or absence of the agents shown. Cells were treated 
with/without metformin (2mM), CCL-11 (5ng/ml), IL-2, IL-4, SDF and CCL22 (10ng/ml) for 12h and 
glucose production was measured by GAGO assay as described in the Methods.  
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Novelty and Significance 
 
What Is Known? 
 
 Observational studies have repeatedly shown benefit of metformin in reducing incidence of 
cardiovascular disease (CVD) events in diabetes. 
 
 Inflammation is understood to contribute to CVD aetiology but it has been difficult to harness 
anti-inflammatory effects for CVD therapy 
 
What New Information Does This Article Contribute? 
 
 Metformin exhibits an anti-inflammatory action in cells and patients, in addition to its known 
anti-hyperglycaemic effects. 
 
 Anti-inflammatory effects of metformin are exerted irrespective of diabetes status, providing a 
non-empirical rationale for further testing of the drug in non-diabetic CVD 
 
Inflammation is understood to contribute to cardiovascular disease (CVD) aetiology but existing 
NSAIDs have shown limited utility in CVD treatment. This suggests that other agents, with different 
anti-inflammatory mechanisms need to be identified for CVD. Observational studies have repeatedly 
shown benefit of metformin in reducing incidence of CVD events in diabetes, which do not seem to 
depend on anti-hyperglycaemic effects alone. In this study, we investigated anti-inflammatory effects 
of metformin, as these may contribute to the CVD benefit of this drug. We find that this drug acts by 
inhibiting the NF-B signaling pathway upstream of IKKIn further work we find that anti-
inflammatory effects of metformin are exerted irrespective of diabetes status, including suppression of 
the ageing-related cytokine CCL11 in a non-diabetic heart failure cohort. These results suggest that 
metformin suppresses chronic inflammation by a different mechanism to NSAIDs and provide a non-
empirical rationale for further testing of the drug in non-diabetic CVD. 
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Table 1a. 
Baseline measurements of GoDARTs diabetes cohort 
Variable 
Metformin  
(N=498) 
Sulfonylurea 
(N=172) p-value 
Age (years) (1) 65 (57-72) 69 (61-76) 0.042 
Sex ( % of males)  55 51.2 0.432 
Diabetes duration (years) (1) 2.1 (0.2-5) 0.95 (0.1-4.2) 0.00193 
Body mass index (kg/m2) (1) 32 (29-35.98) 27.2 (24.4-31.05) 2.26E-14 
HbA1c (%) (1) 8.2 (7.6-9.1) 8.4 (7.5-9.6) 0.471 
Neutrophil to Lymphocyte 
Ratio (1) 1.94 (1.5-2.62) 2.56 (1.868-3.89) 2.47E-06 
Neutrophils (x109/L) (1) 4.2 (3.3-5.5) 4.8 (3.775-6.225) 0.00103 
Lymphocyes (x109/L) (1) 2.1 (1.7-2.8) 1.8 (1.4-2.3) 1.19E-05 
Platelets (x109/L) (1) 236 (199-280) 251.5 (198-305.5) 0.133 
C- reactive protein (mg/L) (1) 10 (5-16.75) 10 (4.1-20) 0.854 
Creatinine (umol/L) 86 (75-98) 94.5 (78-120.8) 0.000172 
Bilirubin (umol/L) (1) 9 (7-13) 9 (7-11.75) 0.069 
Albumin (g/L) (1) 44 (42-45) 41 (38-43) 1.35E-10 
Urea (mmol/L) (1)  5.8 (4.8-6.8) 6.6 (5.075-9.325) 0.000644 
    
Medications     
Angiotension-converting 
enzyme inhibitors, n (%)  41 23.8 8.53E-05 
Angiotensin receptor blockers, 
n (%)  11.8 7 0.0999 
Beta-blocker, n (%)  32.1 28.5 0.428 
Digoxin, n (%)  4.4 9.9 0.0143 
Anticoagulants, n (%)  6 10.5 0.0758 
Calcium channel blocker, n (%)  30.5 24.4 0.154 
Antiplatelets, n (%)  37.3 31.4 0.19 
(1) Median (Inter-quartile Range);  
GoDARTS : Genetics of Diabetes Audit and Research in Tayside Scotland. 
 
Table 1b. Regression coefficients of linear model (log-NLR) 
  Estimate 
Std. 
Error 95% CI p-value 
Sex=M 0.054775 0.031656 (-0.00727,0.117) 0.084038 
Age  -0.035556 0.012157 (-0.0594,-0.0117) 0.003567 
Age2 0.000281 0.000095 (9.51e-05,0.000467) 0.003163 
log(NLR) at 
baseline 0.498068 0.030933 (0.437,0.559) < 10-5 
Group=Metformin -0.093859 0.037702 (-0.168,-0.0200) 0.013037 
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Table 1c. Regression coefficients of linear model – Baseline NLR > Median  
  Estimate 
Std. 
Error 95% CI p-value 
Sex=M 0.1202 0.0427 (0.0364,0.204) 0.0052 
Age  -0.0268 0.0149 (-0.0561,0.00241) 0.0730 
Age2 0.0002 0.0001 (-1.037e-05,0.000444) 0.0623 
log(NLR) at 
baseline 0.2758 0.0559 (0.166,0.385) < 10-5 
Group=Metformin -0.1596 0.0551 (-0.268,-0.0517) 0.0040 
 
Table 1d. Regression coefficients of logistic model (NLR_12 < NLR_0) 
  Estimate Std. 
Error 
95% CI p-value 
Sex=M -0.2280 0.1703 (-0.562,0.106) 0.1804 
Age  0.1450 0.0669 (0.0139,0.276) 0.0302 
Age2 -0.0012 0.0005 (-0.00218,-0.000133) 0.0267 
log(NLR) at 
baseline 1.9456 0.2128 (1.528,2.363) < 10-5 
Group=Metformin 0.6054 0.2078 (0.198,1.013) 0.0036 
 
Table 1e. Regression coefficients of logistic model - Baseline NLR > Median 
  Estimate Std. 
Error 
95% CI p-value 
Sex=M -0.4841 0.2419 (-0.958,-0.00992) 0.0454 
Age  -0.0090 0.0104 (-0.0294,0.0114) 0.3869 
log(NLR) at 
baseline 2.2827 0.4423 (1.416,3.15) < 10-5 
Group=Metformin 0.6478 0.3219 (0.0168,1.279) 0.0442 
 
Table 1f. Summary of GoDARTS analyses, comparing NLR in metformin and sulfonylurea 
groups  
Group analysed 12 month geometric mean NLR  
 
metformin versus sulfonylurea  
% difference (95% CI)  
12 month NLR < 0 month NLR 
 
O.R., metformin versus 
sulfonylurea (95% CI) 
All subjects -9% (2-15) 1.83 (1.22-2.75) 
NLR above group 
median 
-15% (5-23) 1.91 (1.02-3.59) 
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Table 2a ANOVA of heart failure cohort with treatment (without or with metformin) as main 
factor with covariate analysis.  
Significance is taken as * p < 0.01. (n=27).  
 Covariate 
Change in cytokine BMI  BMI & FIRI 
Eotaxin/CCL11 F(1,26) = 9.881; p = 0.004* F(1,26) = 9.135; p = 0.006* 
IL-2 F(1,26) = 9.089; p = 0.006* F(1,26) = 8.078; p = 0.009* 
IL-4 F(1,26) = 8.324;p = 0.008* F(1,26) = 7.148; p = 0.014 
MDC/CCL22 F(1,26) = 9.887; p = 0.004* F(1,26) = 9.846; p = 0.005* 
SDF1αβ/CXCL12 F(1,26) = 16.468; p = 0.000* F(1,26) = 14.661; p = 0.001* 
 
Table 2b Correlation between change in BMI and the cytokines that were significantly affected 
by metformin treatment.  
A Pearson correlation was used. Significance is only noted with drug treatment for those listed (p < 
0.01). 
 With metformin (n=20) Without metformin (n=13) 
Change in cytokine Correlation 
coefficient 
p-value Correlation 
coefficient 
p-value 
MDC/CCL22 -0.625 0.003* 0.077 0.804 ns 
SDF1αβ/CXCL12 -0.620 0.004* -0.103 0.738 ns 
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Supplementary Materials 
Expanded Methods 
I. Animal and Cell Studies 
Metformin and rapamycin came from Calbiochem, AICAR and A769662 (Tocris), 
TNFα (e-bioscience), recombinant CINC1/CXCL1, CCL-11, IL-2, IL-4, SDF and 
CCL22 (R&D systems), mouse IL-6 (Sigma) and recombinant mouse IL-1β (Life 
Technologies). The phospho-acetyl-CoA carboxylase (ACC) Ser79 antibody was a 
generous gift from the DSTT (University of Dundee). The total ACC (Cat. number 
3662), total AMPKα (2603), phospho-AMPKα Thr172 (2535), total S6 (2217), 
phospho-S6 Ser240/244 (2215), total p70 S6 kinase (2708), phospho-p70 S6 kinase 
Thr389 (9205), phospho-Raptor Ser 792 (2083), phospho IKKα/β Ser176/177 
(2078), IKKα/β Ser176/180 (2697), total IκB, pNF-κB, total IKKα and total IKKβ (NF-
κB sampler kit 9936) antibodies were from CST. Anti-sheep HRP (31480) and anti-
rabbit HRP (31460) both came from Thermo and anti-mouse HRP was from 
Calbiochem (JA1200). BI605906 was a generous gift from Prof Sir Philip Cohen. 
Animal Care  
C57BL/6 female mice (Charles River, 8-41 weeks) were maintained under a 12 
hours:12hours light:dark cycle (holding room lights on at 06:00; off at 18:00) at 
22±1◦C and 50% humidity. Mice had ad libitum access to standard chow diet (7.5% 
fat, 75% carbohydrate and 17.5% protein by energy (RM1 diet; Special Diet 
Services) and water. All animal care protocols and procedures were performed in 
accordance with current regulations.  
AMPKα1α2-null (AMPK KO) mice were maintained under a 12-hour light/12-hour 
dark cycle with free access to water and standard mouse diet (in terms of energy: 
65% carbohydrate, 11% fat, 24% protein). These AMPK catalytic subunit deficient 
mice were generated as previously described (1). All procedures were performed in 
accordance with the principles and guidelines established in the European 
Convention for the Protection of Vertebrate Animals Used for Experimental and 
Other Scientific Purposes (Council of Europe, ETS no. 123, 1991).  
 
 
Hepatocyte Extraction 
Mice were killed by cervical dislocation following guidelines set out by the Animals 
(Scientific Procedures) Act 1986. An incision into the abdomen was followed by 
dissection of the skin, abdominal cavity and diaphragm to expose the liver, kidney, 
inferior vena cava and portal vein. The superior vena cava was clamped to isolate 
the hepatic system and the inferior vena cava was cannulated just above the kidney 
with a 25G butterfly needle and clamped in place. Immediately after cannulation, the 
portal vein was cut. Successful cannulation was determined when the liver cleared 
quickly of blood and became pale throughout. The liver was perfused with 50ml pre-
warmed perfusion buffer (137mM NaCl, 7mM KCl, 0.7mM Na2HPO4, 10mM HEPES 
pH 7.65 filter sterilized (0.2 µm) with 0.1% EDTA 0.5M pH 8 added just prior to use) 
at a rate of 5ml/min. After 10 min, the liver was perfused with 50ml digestion buffer 
(perfusion buffer without EDTA with 5.1mM CaCl2 and 20mg collagenase (from 
Clostridium histolyticum type IV, Sigma)); added at a rate of 5ml/min. After digestion, 
the liver was excised from the abdominal cavity and transferred to a cell culture hood 
in a 10cm dish. The liver was resuspended in 10ml of plating media (440ml M199 + 
Glutamax (1x), Invitrogen; 5ml Pen/Strep (100x), Invitrogen; 6.7ml BSA (7.5%), 
Invitrogen; 50ml FBS (foetal bovine serum); 7.7µl Insulin Actrapid (100U/ml), Novo 
Nordisk; 100µl T3 (thyroid hormone 1mM stock), Sigma; 25µl Dexamethasone 
(10mM stock), Merck) and the hepatocytes isolated by gently agitating the liver. Cells 
were filtered through a 100 µm cell strainer and this process was repeated 4 more 
times until a final volume of 50ml was obtained.  Hepatocytes were pelleted by 
centrifugation at 400 rpm for 5 min using no acceleration or braking. The supernatant 
was discarded and the cell pellet resuspended in 25ml plating media by gentle 
inversion. Cell viability was determined by 0.04% Trypan blue staining and the cell 
number determined using a haemocytometer. Cell viability of >90% was required for 
experimental use.  
 
Cell Culture and Lysis for Immunoblotting 
All cells were maintained in an incubator at 37ºC and 5% CO2. For lysate and RT-
PCR experiments, primary mouse hepatocytes were plated in 6-well plates (2.5 x 105 
cells/well in 2ml media) while for glucose assay experiments, primary mouse 
hepatocytes were plated in 12-well plates (1.25 x 105 cells/well in 1ml media). After 4 
hours, plating media was removed, cells were washed with warmed PBS and 
overnight media (500ml M199 + Glutamax (1x); 5ml Pen/Strep (100x); 25µl 
Dexamethasone (10mM stock)) was added at 2ml per well. Cells were incubated 
overnight and experiments were performed the following day. 
BMDMs were grown from mouse bone marrow in RPMI 1640 medium supplemented 
with 10% FBS (Life Technologies) and 10ng/ml M-CSF (R&D systems). Cells were 
given fresh medium and growth factor on day 3 of culture. On day 6, BMDM cultures 
were supplemented with 100ng/ml IFNγ (for M1 differentiation; R&D systems), 
20ng/ml IL-4 (for M2 differentiation; R&D systems), or 100ng/ml LPS (for activation; 
premium grade from Sigma, expected to activate TLR2 and TLR4) in the presence or 
absence of drug treatments for the final 24h. 
Prior to SDS-PAGE, cells were lysed by scraping into buffer A: (50mM Tris acetate 
pH7.5, 1% (w/v) Triton X100, 1mM EDTA, 1mM EGTA, 0.27M sucrose, 50mM NaF, 
1mM sodium orthovanadate, 10mM β-glycerophosphate, 5mM sodium 
pyrophosphate, 1mM benzamidine, 0.2mM phenylmethylsulfonyl fluoride (PMSF) 
and 0.1% (v/v) β-mercaptoethanol) then prepared for SDS-PAGE as follows. The 
lysates were centrifuged at 13 000 g for 15 min, and the supernatants were 
removed. Protein concentration was determined by Bradford assay (Bio-Rad). The 
supernatant was loaded in equal amounts of protein and subjected to 4-20% 
gradient SDS-PAGE and subsequently were transferred to nitrocellulose 
membranes. Primary antibody incubations were performed at dilutions 
recommended by the manufacturer or determined by us in 5% milk TBS-T. All 
incubations were done at 4°C, overnight after a 1 hr block in 5% milk TBS-T. The 
secondary antibody was used at 1:5000 dilution for 1 hr at room temperature. 
Proteins were visualised using the enhanced chemiluminescence (ECL) system 
(Amersham) onto X-ray film (Kodak). Immunoblot densitometry for each antibody 
was performed with Image Studio Lite version 5.2 (LI-COR). Each blot is 
representative of experiments carried out at least three times. 
Glucose Assay 
Treatment of cells for hepatocyte glucose production was performed using primary 
mouse hepatocytes plated in 12-well plates (1.25 x 105 cells/well in 1ml media). 
Glucose production was determined after a 12 hour incubation period in 750µl 
glucose-free DMEM (11966; Life Technologies) supplemented with 1% Pen/Strep, 
lactate (Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone 
(dex; Merck) with or without drugs/cytokines under investigation. At the end of the 
incubation period of 12 hours, 500µl of medium was collected and glucose 
concentration determined by GAGO assay (GAGO-20; Sigma) by a modified 
protocol scaled down to a 96-well plate format. 50µl of sample medium followed by 
100µl assay reagent was added to each well with no time delay. Following incubation 
at 37oC for 30 minutes, 100µl 12N H2SO4 was added to each well and mixed using a 
multi-well pipette. Absorbance was measured at 540 nm. Each column consists of 
data from at least 12 wells of cells, six each from two mice. 
RT-PCR 
Primary mouse hepatocytes were incubated for 8 hours in 1ml glucose-free DMEM 
(11966; Life Technologies) supplemented with 1% pen/strep, lactate 
(Sigma)/pyruvate (Life Technologies) (10:1 mM) and 100nM dexamethasone (dex; 
Merck) with or without drugs under investigation. After this incubation period, media 
was removed and cells were washed once with warmed PBS. 350µl of Buffer RLT 
from the Rneasy MINI KIT (Qiagen) plus 10% β-mercaptoethanol was added to each 
well. Plates were then placed on ice for 10 min, followed by a cell harvest and 
samples were snap-frozen immediately in LN2. Total RNA was extracted using 
QIAshredder (Qiagen) and Rneasy MINI KIT (Qiagen) as per the manufacturer’s 
instructions. cDNA was synthesized from 1µg RNA using RQ1 Rnase-Free Dnase kit 
(Promega) and ImProm-II Reverse Transcription System (Promega). cDNA was 
diluted in nuclease-free water 1:10 prior to use.  
Nucleospin RNA II Total RNA isolation kit (Macherey-Nagel) was used to isolate 
RNA from macrophages. cDNA was synthesized from 0.5µg RNA using High 
Capacity cDNA Reverse Transcription Kit (4368814, Thermo Fisher Scientific). 
cDNA was diluted in nuclease-free water 1:2 prior to use. 
Real-time PCR was carried out using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems) using TaqMan 2x Universal PCR Master Mix (Applied 
Biosystems) and primer/probes mixes as stated (Applied Biosystems). Primer sets 
used were: IL-6 Mm00446190_ml; CXCL1 Mm04207460_m1; 18S Hs03003631_g1; 
IL-1β Mm00434228_m1; CXCL2 Mm00436450_m1; PPARγ Mm01184322_m1; 
FASN Mm00662319_m1; CCL22 Mm00436439_ml; CXCL12 Mm00445553_ml; TBP 
Mm01277042_m1 and SREBP-1c Mm00550338_m1. Cycling conditions were: 50°C 
for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Expression is expressed relative to 18s mRNA for hepatocytes and TBP for 
macrophages (Applied Biosystems) using the 2-ΔΔCt method. Control samples were 
set at a value of 100% and results for all experimental samples were graphed as 
relative expression compared to control. Each column is composed of data from at 
least three separate experiments. 
BMDM studies 
BMDMs were harvested from culture plates using 4mM EDTA in PBS for 10min at 
37°C. Cells were washed in flow cytometry buffer (PBS with 2% FBS and 1mM 
EDTA) and stained using the following antibodies (all BD Bioscience unless stated): 
F4/80 (BM8; e-bioscience), CD11c (HL3), CD206 (C068C2; Biolegend), CD69 
(H1.2F3) and CD40 (3/23). Fc block (4.4G2) was included in all stains. Data were 
acquired on a LSR II flow cytometer (Becton Dickinson) and analysed using FlowJo 
software (TreeStar). BMDM culture supernatants were collected after 24 hours 
treatment with the differentiation or activation conditions. Levels of cytokines were 
quantified by standard sandwich ELISA using paired antibody kits (e-bioscience), 
according to the manufacturer’s instructions.  
Statistical Analyses 
Results in bar graphs are expressed as mean ± SEM. Comparisons between groups 
were made by one-way ANOVA with Dunnett’s or Tukey post-hoc test using Prism. 
Differences were considered statistically significant if P was less than 0.05. *** 
denotes p<0.001; ** denotes p<0.01 and * denotes p<0.05. For studies on the 
plasma, statistical analyses of data were performed using SPSS 14.1. ANOVA and 
Pearson correlation coefficients were calculated.  
 
II. Validation in Clinical Patients 
Population Cohort Study: Diabetes Patient Metformin Exposure and 
Neutrophil-to-Lymphocyte Ratio (NLR). 
Sample Ascertainment  
Patients were ascertained from the Diabetes Audit and Research in Tayside 
Scotland (DARTS) study, which has previously been described in detail (2). In brief, 
all the participants were linked through to the Health Informatics Centre Database to 
retrieve validated prescribing information, clinical information system, all 
haematological and biochemistry data and the Scottish Care Information–Diabetes 
Collaboration (SCI-DC) (REF) that provide additional clinical phenotypic data back to 
1992. Prospective longitudinal data were also collected on these patients. The study 
was approved by the Tayside Regional Ethics Committee, and informed consent was 
obtained from all subjects since 1997 to DNA and serum collection as part of the 
Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection. Over 
17,000 subjects have participated in this Genetics of DARTS (Go-DARTS) study till 
date, of whom over 9,000 have diabetes. 
Hematological Measurements. 
We analysed the electronically linked records of routine laboratory investigations of 
all the participants from the regional biochemistry and hematological database. The 
total and differential leucocyte counts (including the neutrophils and lymphocytes) 
were determined from peripheral venous blood samples using an automated 
Siemens’ high-volume hematology analyzer, the ADVIA® 2120i System (peroxidase 
method) (3). NLR was calculated as the ratio between (percentage of) neutrophils 
and total lymphocyte counts in the study subjects. 
 
Statistical Analysis 
For the population cohort study, characteristics of patients with or without metformin 
therapy were compared by the chi-square test for categorical variables and by the t 
test or Mann-Whitney U test for continuous variables as appropriate. The effect of 
metformin therapy on NLR were examined together with the significant differences 
found at baseline using linear and logistic regression analysis. The following 
covariates were included: age, sex, HbA1c, BMI, duration of followup, prior 
hospitalisation for COPD, Atrial Fibrilation or Hypertension, and baseline NLR. To 
minimize confounding influences, we performed two different sensitivity analysis. 
First, by using a multivariate model adjusting for potential confounders; second we 
determined a propensity score using a logistic regression model to control for the 
different characteristics of the metformin and sulfonylurea groups. A P-value of <0.05 
was considered significant and all statistical analysis for this cohort study were 
performed using R for windows (v3.2.0).   
Randomised Placebo Controlled Study 
The effect of metformin on plasma inflammatory cytokines were further investigated 
in a subset of chronic heart failure (CHF) patients who had participated in a double-
blind, placebo-controlled study of metformin, which has previously been described in 
detail (4). In brief, this study was designed and powered to evaluate the impact of 
metformin on IR and its effects on exercise capacity in non-diabetic IR patients with 
CHF. Every patient who participated in this study, provided written informed consent 
prior to participation in this study, which was approved by the East of Scotland 
Research Ethics Service (www.clinicaltrials.gov: NCT00473876). In this study we 
had shown that metformin treatment significantly improved IR but had no significant 
effect on the primary endpoint of exercise capacity, as measured by peak VO2. 
However, metformin treatment did result in a significant improvement in the minute 
ventilation − carbon dioxide production relationship (VE/VCO2 slope), a pre-specified 
secondary endpoint of this proof of concept study which is of prognostic significance 
in patients with CHF, and in some studies, it has outperformed peak VO2 (5). 
Cytokine Assay  
We analysed plasma from 33 non-diabetic insulin resistant heart failure patients who 
took part in a placebo controlled clinical trial of metformin (4). The plasma was 
analysed using the Bio-Plex Pro Human Chemokine 40-Plex Panel (171-AK99MR2, 
Bio-Rad). The assay was performed following the manufacturer’s instructions using 
the Bio-Plex 200 system (Bio-Rad). Freeze-thaw cycling of samples was avoided to 
prevent cytokine degradation and they were diluted 1:4 (12.5µl of plasma) for the 
assay. 
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Supplementary table I. Cytokine measurements 
  Baseline 
  Placebo (n=13) Metformin (n=20) 
Cytokine (pg/ml) Average SD Average SD 
CCL21/6Ckine 5454.29 2067.61 5890.92 1853.73
BCA-1/CXCL13 28.52 9.54 35.02 13.22 
CTACK/CCL27 1723.32 583.41 1973.63 815.37 
ENA-78/CXCL5 642.91 213 781.07 321.26 
Eotaxin/CCL11 51.4 13.67 60.8 17.69 
Eotaxin-2/CCL24 685.11 518.81 640.79 402.68 
Eotaxin-3/CCL26 56.27 18.48 74.93 60.97 
Fractalkine/CX3CL1 172.05 61.95 237.93 93.3 
GCP-2/CXCL6 20.34 8.37 26.27 14.34 
GM-CSF 128.91 50.39 137.67 52.51 
Gro-α/CXCL1 348.61 83.78 336.15 76.27 
Gro-β/CXCL2 153.61 74.54 235.74 178.19 
I-309/CCL1 83.83 17.2 92.43 18.49 
IFNγ 64.35 20.88 75.98 27.42 
IL-1β 7.53 3.66 9.33 3.84 
IL-2 15.96 5.21 18.87 6.48 
IL-4 32.19 7.45 33.4 9.48 
IL-6 14.14 3.89 17.81 8.58 
IL-8/CXCL8 14.19 4.16 16.9 4.72 
IL-10 46.74 21.99 54.49 22.46 
IL-16 329.73 120.54 364.8 130.41 
IP-10/CXCL10 173.62 67.61 206.57 114.88 
I-TAC/CXCL11 18.02 6.86 23.33 7.83 
MCP-1/CCL2 69.92 33.76 86.03 52.74 
MCP-2/CCL8 56.84 21.19 70.44 38.9 
MCP-3/CCL7 126.6 35.08 146.64 53.26 
MCP-4/CCL13 77.59 46.32 69.26 39.3 
MDC/CCL22 1014.65 290 1151.86 505.54 
MIF 6303.03 5822.99 5681.16 3323.86
MIG/CXCL9 296.66 136.95 404.71 277.22 
MIP-1α/CCL3 10.5 2.02 12.22 3.69 
MIP-1δ/CCL15 7487.28 3978.97 7716.92 4125.49
MIP-3α/CCL20 34.9 79.52 37.84 43.88 
MIP-3β/CCL19 353.04 252.2 463.93 308.82 
MPIF-1/CCL23 446.78 221.81 494.74 211.13 
SCYB16/CXCL16 503.06 216.96 567.01 228.79 
SDF-1α+β/CXCL12 1257.91 423.96 1487.04 500.84 
TARC/CCL17 113.29 81.29 138.35 94.4 
TECK/CCL25 759.25 248.21 896.76 327.17 
TNFα 46.33 10.03 51.18 15.66 
  Change after 4 months metformin treatment     
  Placebo (n=13) Metformin (n=20) BMI (p 
value) 
BMI & 
FIRI (p 
value) Cytokine (pg/ml) Average SD Average SD 
CCL21/6Ckine 99.20 756.47 55.16 2595.81 0.857 0.8 
BCA-1/CXCL13 3.92 7.29 2.34 14.28 0.036 0.029 
CTACK/CCL27 54.09 401.40 -128.67 902.78 0.022 0.032 
ENA-78/CXCL5 29.79 148.93 -60.30 375.81 0.02 0.025 
Eotaxin/CCL11 5.18 8.94 -0.36 17.00 0.004 * 0.006 * 
Eotaxin-2/CCL24 32.73 258.03 -21.23 210.01 0.309 0.356 
Eotaxin-3/CCL26 6.54 13.67 -11.50 54.48 0.038 0.053 
Fractalkine/CX3CL1 0.93 56.10 -25.89 107.44 0.085 0.081 
GCP-2/CXCL6 0.91 6.29 1.05 13.11 0.169 0.216 
GM-CSF 1.52 34.36 3.15 55.77 0.051 0.05 
Gro-α/CXCL1 11.01 54.90 5.89 80.00 0.101 0.106 
Gro-β/CXCL2 32.80 56.92 9.41 120.75 0.317 0.365 
I-309/CCL1 6.16 10.89 -0.69 17.79 0.011 0.014 
IFNγ 6.28 16.04 -1.85 29.38 0.019 0.025 
IL-1β 0.16 2.90 -0.96 4.15 0.116 0.098 
IL-2 1.47 3.17 -0.95 6.96 0.006 * 0.009 * 
IL-4 1.33 4.55 -2.67 11.90 0.008 * 0.014 
IL-6 0.86 3.43 2.75 14.94 0.022 0.027 
IL-8/CXCL8 1.87 3.94 0.20 8.25 0.07 0.072 
IL-10 6.79 14.29 -4.43 27.19 0.019 0.024 
IL-16 32.62 82.96 -19.07 149.55 0.013 0.021 
IP-10/CXCL10 -3.82 52.93 16.13 118.54 0.958 0.893 
I-TAC/CXCL11 2.22 7.06 3.73 13.73 0.989 0.955 
MCP-1/CCL2 12.78 26.27 -5.34 35.48 0.039 0.055 
MCP-2/CCL8 9.01 16.58 -2.92 38.04 0.048 0.071 
MCP-3/CCL7 13.07 31.37 -7.03 55.42 0.025 0.029 
MCP-4/CCL13 -3.31 25.83 3.02 37.95 0.377 0.418 
MDC/CCL22 93.18 244.23 -47.75 453.81 0.004 * 0.005 * 
MIF -1711.46 5475.63 -829.75 3572.37 0.436 0.464 
MIG/CXCL9 52.40 128.26 -3.84 200.65 0.016 0.019 
MIP-1α/CCL3 0.72 1.66 -0.52 2.67 0.013 0.013 
MIP-1δ/CCL15 -300.03 2502.48 515.34 4045.71 0.505 0.368 
MIP-3α/CCL20 -16.84 61.17 -4.44 45.65 0.832 0.991 
MIP-3β/CCL19 97.36 212.33 -77.06 343.62 0.018 0.024 
MPIF-1/CCL23 -16.10 95.08 -29.21 177.39 0.26 0.214 
SCYB16/CXCL16 -11.35 114.84 30.26 203.08 0.083 0.11 
SDF-1α+β/CXCL12 103.67 198.81 -49.25 409.72 0 * 0.001 * 
TARC/CCL17 29.45 72.26 -20.89 96.02 0.022 0.03 
  
Supplementary table II. Metabolic, haemodynamic and other characteristics of patients 
  Baseline   
  Placebo (n=13) Metformin (n=20) p value 
Sex 
Male  12; Female 
1 Male 16; Female 4   
  Average SD Average SD   
Age 64.23 6.99 62.70 7.04 0.408 
Metabolism 
Parameters           
Body Mass Index 29.37 5.11 30.19 5.23 0.319 
Insulin (mU/L) 22.63 11.54 27.47 15.29 0.144 
Glucose (mmol/L) 5.37 0.42 5.61 0.66 0.331 
Fasting Insulin 
Resistance Index (log) 4.90 2.57 6.32 3.92 0.134 
Severity of Heart 
Failure           
Brain Natriuretic Peptide 
(pg/ml) 116.27 131.98 139.09 197.95 0.750 
Ejection Fraction (%) 28.82 8.29 37.29 7.93 0.016 
Haemodynamic 
Conditions          
Resting Systolic Blood 
Pressure (mmHg) 116.54 21.05 107.60 9.68 0.101 
Resting Diastolic Blood 
Pressure (mmHg) 75.15 10.38 69.35 7.15 0.178 
Resting Heart Rate 70.08 21.22 68.60 14.44 0.992 
Peak VO2 (mL/kg/min) 18.02 5.94 19.72 4.75 0.776 
VE/VCO2 slope 30.65 5.31 31.64 6.03 0.244 
Total exercise duration 
(s)  954.15 355.64 1063.80 204.51 0.469 
 
 
 
 
 
 
TECK/CCL25 54.31 180.75 -57.17 354.85 0.019 0.026 
TNFα 4.91 8.98 0.09 18.93 0.03 0.036 
Significance taken as * p < 0.01.  
 
 
 
  
Change after 4 months metformin 
treatment   
  Placebo (n=13) 
Metformin 
(n=20) p value 
  Average SD Average SD   
Metabolism 
Parameters           
Body Mass Index 0.46 0.76 -1.16 1.08 0.000 
Insulin (mU/L) 0.92 7.39 -6.39 9.19 0.044 
Glucose (mmol/L) -0.02 0.75 -0.29 0.50 0.042 
Fasting Insulin 
Resistance Index (log) 0.26 1.77 -1.81 2.53 0.029 
Severity of Heart 
Failure           
Brain Natriuretic Peptide 
(pg/ml) 17.26 122.33 -22.24 91.36 0.383 
Ejection Fraction (%) -0.89 2.52 -1.03 3.61 0.681 
Haemodynamic 
Conditions           
Resting Systolic Blood 
Pressure (mmHg) -7.15 16.18 0.80 14.63 0.049 
Resting Diastolic Blood 
Pressure (mmHg) -4.69 9.22 -0.45 7.84 0.177 
Resting Heart Rate 1.00 11.73 2.70 9.95 0.451 
Peak VO2 (mL/kg/min) 1.25 4.59 -0.91 2.73 0.334 
VE/VCO2 slope 1.86 10.57 -4.52 5.37 0.029 
Total exercise duration 
(s)  7.08 92.03 -22.75 99.45 0.671 
 
Supplementary figure legends 
Supplementary Figure I. Densitometry of blots in main figure 1 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. Bars significantly different from the respective control treatment (+/- 
TNFα) are shown, ***p<0.001, **p<0.01, *p<0.05. N=3 except for IκBa and pACC, 
N=4 
Supplementary Figure II. Densitometry of blots in main figure 2 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. In experiments comparing wild-type (WT) and knockout (KO) 
genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars 
significantly different from the respective control treatment (+/- TNFα) are shown, 
***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance 
between genotypes is depicted. N=3 
Supplementary Figure III. Effect of metformin on gene expression in 
macrophages: genes regulated in hepatocytes 
Macrophages were treated with or without 100ng/ml LPS +/- 2mM metformin for 8h 
followed by cell lysis, RNA extraction and preparation of cDNA for RTPCR using 
primer sets for individual genes shown, as described in the methods. Bars 
significantly different from control treatment, or between two annotated bars are 
shown, ***p<0.001, *p<0.05 
 
Supplementary Figure IV. Effect of metformin on gene expression in 
macrophages and hepatocytes: genes changed by metformin in human 
plasma 
Macrophages (a,b) were treated with/without 100ng/ml LPS +/- 2mM metformin, 
while hepatocytes (c) were treated with/without 10ng/ml TNFα +/- 2mM metformin or 
10mM BI605906 as shown, for 8h followed by cell lysis, RNA extraction and 
preparation of cDNA for RTPCR using primer sets for individual genes shown, as 
described in the methods. Bars significantly different from control treatment, or 
between two annotated bars are shown, ***p<0.001, **p<0.01, *p<0.05 
 
Supplementary Figure V. Densitometry of blots in main figure 5 
Densitometry was carried out as described in the methods to quantify data obtained 
in western blots. In experiments comparing wild-type (WT) and knockout (KO) 
genotype, black bars denote WT genotype, grey bars denote KO genotype. Bars 
significantly different from the respective control treatment (+/- TNFα) are shown, 
***p<0.001, **p<0.01, *p<0.05, except in knockout experiments, where significance 
between genotypes is depicted. N=3 
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